← Back to all trials
Active Not Recruiting
NCT07638878
The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer
Conditions: Lung Cancer (Locally Advanced or Metastatic)
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Enrollment: 30
Sponsor: Guangzhou Medical University
Location: The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong
Summary
To determine the optimal objective response rate (ORR) of tislelizumab combined with albumin-bound paclitaxel and platinum agents in patients with KRAS-mutant lung cancer who are ineligible for curative surgery
Eligibility Criteria
Inclusion Criteria:
1. Ages 18-75 years (inclusive), regardless of gender;
2. Locally advanced (Stage IIIB, IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) confirmed by histology as inoperable for curative intent (according to the 8th edition of the IASLC TNM staging system);
3. Or histologically confirmed inoperable mixed small cell lung cancer containing non-small cell lung cancer components;
4. KRAS gene mutation-positive;
5. KRAS mutation-positive lung cancer not amenable to radical surgery, treated with tislelizumab in combination with nab-paclitaxel and platinum chemotherapy.
Exclusion Criteria:
1. Patients with incomplete key baseline information and treatment data.
2. Patients who refuse to provide written informed consent (ICF).
Source: ClinicalTrials.gov (NCT07638878). StuddyBuddy aggregates publicly available trial information.
